Blog
RSS FeedPosted by Michael Wonder on 27 Feb 2024
Voxelotor for the treatment of patients with sickle cell disease (draft guidance)
27 February 2024 - NICE has issued further draft guidance on the use of voxelotor following an appeal hearing in ...
Posted by Michael Wonder on 27 Feb 2024
Tafamidis meglumine for the treatment of patients with transthyretin amyloidosis with cardiomyopathy
27 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Feb 2024
Setmelanotide acetate for the treatment of people with obesity and hyperphagia associated with Bardet-Biedl syndrome (draft guidance)
22 February 2024 - NICE has published further draft guidance on the use of setmelanotide acetate. ...
Posted by Michael Wonder on 22 Feb 2024
Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE
22 February 2024 - Thousands of people with severe hair loss due to alopecia areata are set to benefit from a ...
Posted by Michael Wonder on 21 Feb 2024
Talazoparib tosylate for the treatment of patients with advanced BRCA mutation positive HER2 negative breast cancer (final guidance)
21 February 2024 - NICE has published final evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment ...
Posted by Michael Wonder on 10 Feb 2024
Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma
9 February 2024 - NICE is reviewing its guidance on the use of isatuximab for the treatment of patients with ...
Posted by Michael Wonder on 07 Feb 2024
Olaparib in combination with abiraterone acetate for the treatment of patients with hormone relapsed metastatic prostate cancer
7 February 2024 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) in combination with abiraterone ...
Posted by Michael Wonder on 07 Feb 2024
Nivolumab with relatlimab for the treatment of patients with unresectable or metastatic melanoma
7 February 2024 - NICE has published final evidence-based recommendations on the use of nivolumab with relatlimab (Opdualag) for the ...
Posted by Michael Wonder on 07 Feb 2024
Belumosudil mesylate for the treatment of patients with chronic graft versus host disease
7 February 2024 - NICE has published final evidence-based recommendations on the use of belumosudil mesylate (Rezurock) for the treatment ...
Posted by Michael Wonder on 05 Feb 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma
2 February 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 04 Feb 2024
Ruxolitinib phosphate for the treatment of patients with non-segmental vitiligo
31 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on using ruxolitinib ...
Posted by Michael Wonder on 02 Feb 2024
Fenfluramine hydrochloride for the treatment of patients with Lennox-Gastaut seizures
31 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Feb 2024
Ivosidenib for the treatment of patients with advanced IDH1 R132 mutation positive cholangiocarcinoma after one or more systemic treatments
31 January 2024 - NICE has published final evidence-based recommendations on the use of ivosidenib (Tibsovo) for the treatment of ...
Posted by Michael Wonder on 31 Jan 2024
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
31 January 2024 - NICE has published evidence-based recommendations on the use of loncastuximab tesirine (Zynlonta) for the treatment of ...
Posted by Michael Wonder on 30 Jan 2024
Treosulphan in combination with fludarabine phosphate before allogeneic stem cell transplantation for patients aged 1 month to 17 years with non-malignant diseases
30 January 2024 - NICE is unable to make a recommendation on the use of treosulphan (Trecondi) in combination with fludarabine ...